Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Company Deals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Fineline Cube Mar 30, 2026
Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Fineline Cube Mar 30, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Fineline Cube Mar 30, 2026
Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026
Company Deals

Shenzhen Keyto Fluid Control Secures Series C Funding for Expansion

Fineline Cube Jan 13, 2023

Shenzhen Keyto Fluid Control Co., Ltd, a China-based manufacturer of precision fluid control components, has...

Company Drug

Xinhua Pharma’s OAB-14 Receives NMPA Approval for Phase I Alzheimer’s Study

Fineline Cube Jan 13, 2023

China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) has announced receiving approval from the National...

Company Deals

Cii Tech Secures Tens of Millions in Pre-Series A Funding for Mass Spectrometry

Fineline Cube Jan 13, 2023

China Innovation Instrument (Cii Tech), a life sciences instrument maker based in Ningbo, has reportedly...

Company Deals

TechnoDerma Raises Series A+ Funding to Advance Dermatology Pipeline

Fineline Cube Jan 13, 2023

TechnoDerma Medicines Inc., a Zhejiang-based developer of dermatology small molecules, has reportedly raised “tens of...

Company Drug

Konruns’ KC1036 Advances to Phase II Study for Lung Adenocarcinoma

Fineline Cube Jan 13, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced receiving approval from the National Medical...

Company Drug

Harbour BioMed’s HBM1020 Receives FDA Approval for US Phase I Study

Fineline Cube Jan 13, 2023

Harbour BioMed (HKG: 2142), a global biotech company operating in the Netherlands, the United States,...

Company

Porton Pharma Solutions to Invest EUR 50 Million in Slovenia Bio-Industry Park

Fineline Cube Jan 13, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions is set to establish a...

Company Digital

ClouDr Partners with Shaanxi Pharmaceutical Firms for Integrated Healthcare Solutions

Fineline Cube Jan 13, 2023

Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), better known as “ClouDr,” has announced...

Company Deals

Syneos Health Partners with Fosun Pharma to Commercialize Serplulimab in US

Fineline Cube Jan 13, 2023

US-based Syneos Health (Nasdaq: SYNH) has revealed a strategic partnership with Fosun Pharma USA Inc.,...

Company Drug

Sanofi’s iGlarLixi Approved in China for Type 2 Diabetes Management

Fineline Cube Jan 13, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that the National Medical Products Administration (NMPA)...

Company Drug

Roche’s Polivy Approved by China’s NMPA for Lymphoma Treatment

Fineline Cube Jan 13, 2023

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the National Medical Products...

Policy / Regulatory

China Launches Eighth Round of National Volume-Based Procurement for 41 Drugs

Fineline Cube Jan 13, 2023

The National Healthcare Security Administration has issued a notice to initiate the COVID-delayed eighth round...

Company

Med Vision Secures A+ Round Financing to Accelerate Digital Therapy Commercialization

Fineline Cube Jan 12, 2023

Hangzhou-based Med Vision Technology Co., Ltd. has successfully completed an A+ round financing, raising several...

Company Drug Legal / IP

MSD China to Take Legal Action Against Market Infringement of Molnupiravir

Fineline Cube Jan 12, 2023

Merck Sharp & Dohme (MSD, NYSE: MRK)’s China unit has issued a WeChat notification vowing...

Company Deals

Med Vision Secures Series A+ Funding to Expand Digital Therapy Portfolio

Fineline Cube Jan 12, 2023

Med Vision, a Hangzhou-based digital therapy specialist, has reportedly raised “tens of millions” of renminbi...

Company Drug

Kexing Pharmaceutical Initiates Phase I Trial for IFN-Alpha-1b Inhalation Solution

Fineline Cube Jan 12, 2023

China-based Kexing Pharmaceutical (SHA: 688136) has announced the enrollment of the first subject and dosing...

Company Deals

Bioantibody Bio Raises RMB 100 Million in Series A Funding Round

Fineline Cube Jan 12, 2023

Bioantibody Biotechnology Co., Ltd, a Nanjing-based in vitro diagnostics (IVD) and biologic company, has reportedly...

Company Deals

Meihua Partners with Getein Biotech to Manufacture COVID-19 Antigen Tests

Fineline Cube Jan 12, 2023

China-based Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA) has announced a strategic partnership with...

Company Drug

CSPC’s Cleviprex Approved for Clinical Study by China’s NMPA

Fineline Cube Jan 12, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...

Policy / Regulatory

China’s Dental Implant VBP Tender Results in Significant Price Cuts

Fineline Cube Jan 12, 2023

The results of the dental implant system-focused volume-based procurement (VBP) tender held in Sichuan have...

Posts pagination

1 … 551 552 553 … 643

Recent updates

  • Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
  • China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio
  • Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise
  • Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
  • Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.